Drug levels of Mycophenolic acid and the genetic mutations that affects these blood levels in patients with autoimmune diseases taking durg mycophenolate mofetil (MMF)
Not Applicable
- Conditions
- Health Condition 1: D898- Other specified disorders involving the immune mechanism, not elsewhere classified
- Registration Number
- CTRI/2023/03/050985
- Lead Sponsor
- Seth GS Medical College and KEM Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Adults of any gender aged 18 years and above, willing to provide a written informed consent
2. Patients who are on MMF for at least 5 days
3. Willing to follow the study protocol
Exclusion Criteria
1. Patients who are critically ill
2. Women who are pregnant or breast feeding
3. Any other reason that in the opinion of the investigator is likely to cause harm to the participant or will adversely affect the results of the study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Serum Mycophenolic acid concentrationsTimepoint: Day 0 (Baseline)
- Secondary Outcome Measures
Name Time Method Pharmacogenetics of UGT1A9, UGT2B7, SLCO1B1, SLCO1B3, IMPDH1, and IMPDH2 genesTimepoint: Day 0 (Baseline)